2024 State of Specialty Spend and Trend Report Webinar

PSG announces the results of the industry’s go-to report on specialty spend and trend.

Watch industry experts Renee Rayburg, RPh, and Jennifer Warren, CPC, CFE, CPhT as they share the most significant trends in specialty drug management. We examine the results of the 2024 State of Specialty Spend and Trend report and discuss how plans can actively manage specialty spend to ensure appropriate utilization of specialty drugs.

Watch the Recording

Key Findings

Despite downward pressure by biosimilars and generic specialty drugs, specialty drug spend and trend increased in 2023
Claim utilization and cost per claim both contribute substantially to specialty drug trend
The percentage of members who use specialty drugs continues to rise, with no signs of leveling off
Humira remains the top specialty drug by spend, but Skyrizi rose from #6 in 2022 to #3 in 2023
Biosimilars are continuing to gain traction in the U.S. market, with especially large increases in market share of the biosimilars for Lucentis and Remicade